Skip to main content
. 2016 Apr 11;7(20):29131–29142. doi: 10.18632/oncotarget.8675

Figure 3. Effect of A674563 on FLT3- and AKT-mediated signaling and overriding of FLT3 ligand-induced drug resistance.

Figure 3

(A) Combination study with FLT3 inhibitor TCS359, and AKT inhibitor MK2206. (B) Anti-proliferation effects of A674563 and FLT3 inhibitors, TCS359 and MLN518, against FLT3-ITD-positive AML cells in the presence of 10 ng/mL FLT3 ligand. (C) Effect of A674563 and MLN518 on FLT3-mediated signaling in MOLM14 (FLT3-ITD/wt) in the presence/absence of FLT3 ligand. (D) Effect of A674563 and MLN518 on AKT-mediated signaling in MOLM14 (FLT3-ITD/wt) in the presence/absence of FLT3 ligand.